Expertise in
8
conditions

Dr. Barbara A. Degar

Pediatric Hematology Oncology
44 Binney St, Jimmy Fund Clinic, 
Boston, MA 
Expertise in
8
conditions
44 Binney St, Jimmy Fund Clinic, 
Boston, MA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Barbara Degar is a Pediatric Hematologist Oncology provider in Boston, Massachusetts. Dr. Degar is highly rated in 8 conditions, according to our data. Her top areas of expertise are Hemophagocytic Lymphohistiocytosis, Non-Langerhans-Cell Histiocytosis, Histiocytosis, and Reticulohistiocytoma.

Her clinical research consists of co-authoring 38 peer reviewed articles and participating in 8 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Pediatric Hematology Oncology
Licenses
Pediatric Hematology-Oncology in MA
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
BMC HealthNet
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
Cigna
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Mass General Brigham Health Plan
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Tufts
  • HMO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
View 4 Less Insurance Carriers -

Locations

44 Binney St, Jimmy Fund Clinic, Boston, MA 02115

Additional Areas of Focus

Dr. Degar has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Immune Thrombocytopenic Purpura (ITP)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

Phase II Study of Clofarabine in Patients With Recurrent or Refractory Langerhans Cell Histiocytosis and LCH-related Disorders
Phase II Study of Clofarabine in Patients With Recurrent or Refractory Langerhans Cell Histiocytosis and LCH-related Disorders
Enrollment Status: Active_not_recruiting
Publish Date: September 26, 2025
Intervention Type: Drug
Study Drug: Clofarabine
Study Phase: Phase 2
Risk-Stratified Therapy for Acute Myeloid Leukemia in Down Syndrome
Risk-Stratified Therapy for Acute Myeloid Leukemia in Down Syndrome
Enrollment Status: Active_not_recruiting
Publish Date: August 01, 2025
Intervention Type: Drug, Other
Study Drugs: Asparaginase, Erwinia Asparaginase, Cytarabine, Daunorubicin, Etoposide, Mitoxantrone, Thioguanine
Study Phase: Phase 3
A Phase II Trial of Epigenetic Priming in Patients With Newly Diagnosed Acute Myeloid Leukemia
A Phase II Trial of Epigenetic Priming in Patients With Newly Diagnosed Acute Myeloid Leukemia
Enrollment Status: Active_not_recruiting
Publish Date: May 18, 2025
Intervention Type: Drug, Combination product, Biological
Study Drugs: Methotrexate, Hydrocortisone, Azacitidine, Decitabine, Cytarabine, Daunorubicin, Etoposide, Idarubicin, Fludarabine, Mitoxantrone, Erwinia Asparaginase, Sorafenib, Granulocyte Colony-Stimulating Factor, Dexrazoxane
Study Phase: Phase 2
A Phase III Study for Patients With Newly Diagnosed Acute Promyelocytic Leukemia (APL) Using Arsenic Trioxide and All-Trans Retinoic Acid
A Phase III Study for Patients With Newly Diagnosed Acute Promyelocytic Leukemia (APL) Using Arsenic Trioxide and All-Trans Retinoic Acid
Enrollment Status: Active_not_recruiting
Publish Date: November 07, 2024
Intervention Type: Other, Drug
Study Drugs: Arsenic Trioxide, Cytarabine, Dexamethasone, Idarubicin, Mitoxantrone, Tretinoin
Study Phase: Phase 3
An Open-label, Single Arm, Multicenter Study to Broaden Access to Emapalumab, an Anti-Interferon Gamma (Anti-IFNγ) Monoclonal Antibody, and to Assess Its Efficacy, Safety, Impact on Quality of Life, and Long-term Outcome in Pediatric Patients With Primary Hemophagocytic Lymphohistiocytosis
An Open-label, Single Arm, Multicenter Study to Broaden Access to Emapalumab, an Anti-Interferon Gamma (Anti-IFNγ) Monoclonal Antibody, and to Assess Its Efficacy, Safety, Impact on Quality of Life, and Long-term Outcome in Pediatric Patients With Primary Hemophagocytic Lymphohistiocytosis
Enrollment Status: Completed
Publish Date: March 12, 2024
Intervention Type: Drug
Study Drug: Emapalumab
Study Phase: Phase 3
A Phase 2/3 Open-label Single Arm Multicentre Study to Assess Safety Tolerability Pharmacokinetics and Efficacy of i.v. Administrations of NI-0501 an Anti-IFNγ mAb in Paediatric Patients With Primary Haemophagocytic Lymphohistiocytosis
A Phase 2/3 Open-label Single Arm Multicentre Study to Assess Safety Tolerability Pharmacokinetics and Efficacy of i.v. Administrations of NI-0501 an Anti-IFNγ mAb in Paediatric Patients With Primary Haemophagocytic Lymphohistiocytosis
Enrollment Status: Completed
Publish Date: February 21, 2023
Intervention Type: Biological
Study Phase: Phase 2/Phase 3
A Multicenter Study for the Long-term Follow-up of HLH Patients Who Received Treatment With NI-0501, an Anti-interferon Gamma Monoclonal Antibody
A Multicenter Study for the Long-term Follow-up of HLH Patients Who Received Treatment With NI-0501, an Anti-interferon Gamma Monoclonal Antibody
Enrollment Status: Completed
Publish Date: June 28, 2022
Intervention Type: Drug
Study Phase: Phase 2/Phase 3
AML08: A Phase II Randomized Trial of Clofarabine Plus Cytarabine Versus Conventional Induction Therapy And A Phase II Study Of Natural Killer Cell Transplantation In Patients With Newly Diagnosed Acute Myeloid Leukemia
AML08: A Phase II Randomized Trial of Clofarabine Plus Cytarabine Versus Conventional Induction Therapy And A Phase II Study Of Natural Killer Cell Transplantation In Patients With Newly Diagnosed Acute Myeloid Leukemia
Enrollment Status: Completed
Publish Date: August 10, 2021
Intervention Type: Drug, Device
Study Phase: Phase 3
View 7 Less Clinical Trials

38 Total Publications

Identifying Targeted Therapies for CBFA2T3::GLIS2 Acute Myeloid Leukemia.
Identifying Targeted Therapies for CBFA2T3::GLIS2 Acute Myeloid Leukemia.
Journal: Research square
Published: June 05, 2025
Similar Doctors
Expertise in
12
conditions
Dr. Rachael Grace
Pediatric Hematology Oncology
Expertise in
12
conditions
Dr. Rachael Grace
Pediatric Hematology Oncology

Children's Hospital Pediatric Associates, Inc

300 Longwood Ave, 
Boston, MA 
 (0.1 miles away)
617-355-6000
Languages Spoken:
English
See accepted insurances

Rachael Grace is a Pediatric Hematologist Oncology provider in Boston, Massachusetts. Dr. Grace is highly rated in 12 conditions, according to our data. Her top areas of expertise are Pyruvate Kinase Deficiency, Immune Thrombocytopenic Purpura (ITP), Hemolytic Anemia, Splenectomy, and Gallbladder Removal.

Expertise in
11
conditions
Dr. Steven G. Dubois
Pediatric Hematology Oncology
Expertise in
11
conditions
Dr. Steven G. Dubois
Pediatric Hematology Oncology
450 Brookline Ave, Dana-farber Cancer Institute, 
Boston, MA 
 (0.1 miles away)
617-632-5460
Languages Spoken:
English
See accepted insurances

Steven Dubois is a Pediatric Hematologist Oncology provider in Boston, Massachusetts. Dr. Dubois is highly rated in 11 conditions, according to our data. His top areas of expertise are Ewing Sarcoma, Neuroblastoma, Embryonal Tumor with Multilayered Rosettes, and Osteosarcoma.

Expertise in
14
conditions
Dr. Matthew M. Heeney
Pediatric Hematology Oncology
Expertise in
14
conditions
Dr. Matthew M. Heeney
Pediatric Hematology Oncology
300 Longwood Ave, Fegan 704, 
Boston, MA 
 (0.1 miles away)
617-355-7700
Languages Spoken:
English
See accepted insurances

Matthew Heeney is a Pediatric Hematologist Oncology provider in Boston, Massachusetts. Dr. Heeney is highly rated in 14 conditions, according to our data. His top areas of expertise are Sickle Cell Disease, Congenital Hemolytic Anemia, Hemolytic Anemia, Hemoglobinopathy, and Splenectomy.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Degar's expertise for a condition
ConditionClose
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile